Reasons for anti-vegf treatment discontinuation in real clinical practice: results of a phone survey of patients with macular diseases

Abstract

Background. Anti-VEGF therapy is currently regarded as the “gold standard” for the treatment of many macular diseases, while the results of its application in real clinical practice are often inferior to those from randomized clinical trials.

Materials and methods. A study group was formed on the basis of a retrospective analysis of the medical data of patients who received anti-VEGF therapy with ranibizumab and/or aflibercept according to registered indications, and who discontinued their follow-up in the clinic (n = 214). A phone survey of patients concerning the reasons for loss to follow-up with a statistical analysis of the obtained data was carried out.

Results. The majority of patients (81.3%) discontinued observation in the clinic within two years from the start of therapy (the median duration of treatment was 7 (3; 18) months). Patients with all considered diseases had an increase in best corrected visual acuity during treatment (p < 0.000001), which confirms the high efficiency of the method. According to the results of the phone survey, the following categories of respondents were identified: complete cessation of treatment – 120 (56.1%) patients, change of clinic – 20 (9.3%), death – 23 (10.7%), status not established – 51 (23.8%). The most frequent reasons for stopping treatment were dissatisfaction with its results (59 cases; 49.2%), financial burden (49; 40.8%), and systemic comorbidities (24; 20.0%).

Conclusion. Searching approaches to increase patients’ treatment adherence is one of the priorities for improving anti-VEGF therapy.

Keywords

patients’ phone survey / anti-VEGF therapy / age-related macular degeneration / diabetic macular edema / macular edema due to retinal vein occlusion / myopic choroidal neovascularization / loss to follow-up / real clinical practice

References

[1] World Health Organization. Adherence to long-term therapies: evidence for action. [edited by Eduardo Sabaté]. WHO; 2003. Available from: https://apps.who.int/iris/handle/10665/42682.

[2] Mehta H, Tufail A, Daien V, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127-146. https://doi.org/10.1016/j.preteyeres.2017.12.002.

[3] Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. British Ophthalmol. 2015;99(2): 220-226. https://doi.org/10.1136/bjophthalmol-2014-305327.

[4] Нероев В.В., Зайцева О.В., Михайлова Л.А. Заболеваемость диабетической ретинопатией в Российской Федерации по данным Федеральной статистики // Российский офтальмологический журнал. – 2018. – Т. 11. – № 2. – С. 5–9. [Neroev VV, Zaytseva OV, Mikhailova LA. Incidence of diabetic retinopathy in the Russian Federation according to Federal statistics. Russian ophthalmological journal. 2018;11(2):5-9. (In Russ.)] https://doi.org/10.21516/2072-0076-2018-11-2-5-9.

[5] Коротких С.А., Бобыкин Е.В., Назарова Н.С., и др. Антиангиогенная терапия неоваскулярных заболеваний макулярной области (отдаленные результаты) // Вестник офтальмологии. – 2016. – Т. 132. – № 1. – С. 76–84. [Korotkikh SA, Bobykin EV, Nazarova NS, et al. Long-term outcomes of anti-angiogenic therapy for macular neovascular disorders. Russian annals of ophthalmology. 2016;132(1):76-84. (In Russ.)] https://doi.org/10.17116/oftalma2016132176-84.

[6] Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year’s treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol. 2009;148(3):409-413. https://doi.org/10.1016/j.ajo.2009.04.001.

[7] Oishi A, Mandai M, Nishida A, et al. Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration. Eur J Ophthalmol. 2011;21(6):777-782. https://doi.org/10.5301/EJO.2011.7430.

[8] Boulanger-Scemama E, Querques G, About F, et al. Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol. 2015;38(7):620-627. https://doi.org/10.1016/j.jfo.2014.11.015.

[9] Бобыкин Е.В. Влияние уровня комплаенса на эффективность антиангиогенной терапии неоваскулярной формы возрастной макулярной дегенерации // Вестник офтальмологии. – 2014. – Т. 130. – № 4. – С. 88–96. [Bobykin EV. The influence of patient compliance with antiangiogenic therapy on its efficacy for neovascular age-related macular degeneration. Russian annals of ophthalmology. 2014;130(4):88-96. (In Russ.)]

RIGHTS & PERMISSIONS

Bobykin E.V., Krokhalev V.Y., Beresneva N.S., Buslaev R.V., Morozova O.V.